Farmacoriflessioni
Antileucotrieni nel bambino con “viral wheezing” ricorrente
THE USE OF ANTILEUKOTRIENES IN CHILDREN WITH RECURRENT VIRAL WHEEZING
ATTILIO BONER1, GIORGIO LONGO2, STEFANO MICELI SOPO3
1Clinica Pediatrica, Policlinico “G.B. Rossi”, Università di Verona
2Clinica Pediatrica, IRCCS “Burlo Garofolo”, Trieste
3Dipartimento di Scienze Pediatriche, Università Cattolica del Sacro Cuore, Roma
Marzo 2005 - pagg. 171 -173
Abstract
In children with frequent wheezing, frequent and serious episodes of asthmatic dispnoea
and risk factors for asthma and atopia, low-dose inhaled steroids should be used as preventive
treatment since bronchial inflammation is primarily due to eosinophils. In children with the same
characteristics but with no risk factors for asthma and atopia, bronchial inflammation is
mostly sustained by neutrophils and their mucus is rich of leukotrienes, hence suggesting the
use of montelukast. It is reasonable to reserve any preventive treatment only to those children
with a frequent recurrence of acute and clinically important episodes.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
1. Global Iniziative for Asthma (GINA). Global
strategy for asthma management and prevention.
National Heart, Lung and Blood Istitute/
WHO Workshopo Report 2002.
2. McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane DatabaseSystRev 2000;(2):CD001107.
3. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000; 162(4 Pt 1):1403-6.
4. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108(3):E48.
5. Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, Tozzi CA, Polos P. Montelukast reduces asthma exacerbations in 2 to 5-year old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171(4):315-22.
2. McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane DatabaseSystRev 2000;(2):CD001107.
3. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med 2000; 162(4 Pt 1):1403-6.
4. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108(3):E48.
5. Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, Tozzi CA, Polos P. Montelukast reduces asthma exacerbations in 2 to 5-year old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171(4):315-22.
Corrispondenza: longog@burlo.trieste.it